Imexon - AmpliMed

Drug Profile

Imexon - AmpliMed

Alternative Names: Amplimexon; BM 06002

Latest Information Update: 04 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AmpliMed
  • Class Antineoplastics; Antivirals; Hexanones; Small molecules
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Reactive oxygen species stimulants; Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Multiple myeloma; Ovarian cancer; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer; Lung cancer; Malignant melanoma; Multiple myeloma; Non-Hodgkin's lymphoma; Ovarian cancer; Prostate cancer
  • Discontinued Pancreatic cancer

Most Recent Events

  • 04 Aug 2015 No recent reports on development identified - Phase-I for Breast cancer, Lung cancer and Prostate cancer in USA (IV)
  • 04 Aug 2015 No recent reports on development identified - Phase-I/II for Malignant melanoma, Multiple myeloma, and Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV)
  • 01 Jul 2013 Handok Pharmaceuticals is now called Handok Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top